Tonghua Dongbao’s 2025 annual performance pre-profit announcement
Securities code: 600867 Securities abbreviation: Tonghua Dongbao Announcement number: 2026-008 Tonghua Dongbao Pharmaceutical Co., Ltd.
2025 annual performance pre-profit announcement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
This performance forecast is applicable to situations where net profit turns from loss to profit.
Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is expected to achieve a net profit attributable to the owners of the parent company of approximately 1,242.13 million yuan in 2025, which will turn losses into profits compared with the same period last year.
After deducting non-recurring gains and losses, the net profit after deducting non-recurring gains and losses attributable to the owners of the parent company in 2025 will be approximately RMB 402.21 million.
1. Performance forecast for this period
(1) Performance forecast period
January 1, 2025 to December 31, 2025.
(2) Performance forecast
According to preliminary calculations by the company's financial department, the net profit attributable to the owners of the parent company is expected to be approximately 1,242.13 million yuan in 2025, which will turn losses into profits compared with the same period last year.
It is expected that the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, will be approximately RMB 402.21 million in 2025.
This performance forecast has not been audited by a certified public accountant.
2. Operating performance and financial status of the same period last year
(1) In 2024, the total profit will be -143.7538 million yuan. Net profit attributable to owners of the parent company: -42.7232 million yuan. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses: -9.1954 million yuan.
(2) Earnings per share: -0.02 yuan.
3. Main reasons for changes in performance in this period
In 2025, the company's net profit attributable to the owners of the parent company turned a profit compared with the same period last year. The details are as follows:
(1) Impact of main business
In the domestic market, the company relied on the advantage of winning the bid for this insulin centralized procurement to promote the rapid increase in volume of insulin analog products such as aspart and glargine, and its market share increased rapidly. At the same time, products such as liraglutide injection and empagliflozin tablets also achieved good growth, and the coordinated efforts of multiple categories drove domestic sales revenue to rise significantly compared with the previous period.
The company's internationalization strategy has achieved remarkable results, and its export revenue has increased significantly.
(2) Impact of non-operating profits and losses
The company generated revenue from the transfer of equity in Xiamen Tebao Bioengineering Co., Ltd., resulting in a substantial increase in net profit.
4. Risk warning
The company has no uncertain factors that affect the accuracy of this performance forecast.
The company's current performance estimates are preliminary calculations made by the company's financial department based on its own professional judgment and have not been audited by a certified public accountant.
5. Other explanations
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the company's officially disclosed 2025 annual report. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Tonghua Dongbao Pharmaceutical Co., Ltd.
January 27, 2026